NetworkNewsBreaks – TC BioPharm (Holdings) PLC (NASDAQ: TCBP) Executes Non-Binding LOI to Expand Its Therapeutic Platform
TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, is announcing the execution of a non-binding letter of intent (“LOI”). According to the announcement, the LOI is part of the company’s M&A strategy intended to expand its therapeutic platform and leverage natural killer (“NK”) cells to treat solid tumors and other indications. The target asset acquisition covers the proprietary manufacturing process of two allogeneic CAR-NK therapeutics, both of which the company believes are valuable as monotherapies and in conjunction with TCB-008 in the future. The terms of the LOI…







